Establishment Labs Holdings Inc. (NASDAQ:ESTA) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Establishment Labs Holdings Inc. (NASDAQ:ESTA) has been given a consensus recommendation of “Moderate Buy” by the eight ratings firms that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating on the company. The average 12 month target price among brokerages that have covered the stock in the last year is $78.8571.

A number of analysts have recently issued reports on the stock. Needham & Company LLC reissued a “buy” rating and issued a $84.00 price objective on shares of Establishment Labs in a research note on Monday, January 12th. JPMorgan Chase & Co. increased their price target on Establishment Labs from $71.00 to $80.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 17th. Mizuho boosted their price objective on Establishment Labs from $85.00 to $90.00 and gave the company an “outperform” rating in a research report on Wednesday, December 17th. BTIG Research increased their target price on Establishment Labs from $81.00 to $86.00 and gave the stock a “buy” rating in a research report on Wednesday, December 31st. Finally, Canaccord Genuity Group boosted their price target on Establishment Labs from $72.00 to $85.00 and gave the stock a “buy” rating in a report on Wednesday, December 17th.

Establishment Labs Stock Up 3.7%

ESTA stock opened at $68.79 on Friday. The business’s 50-day moving average price is $70.11 and its 200-day moving average price is $54.82. The stock has a market cap of $2.00 billion, a P/E ratio of -24.22 and a beta of 0.99. The company has a quick ratio of 2.10, a current ratio of 3.33 and a debt-to-equity ratio of 15.06. Establishment Labs has a twelve month low of $26.56 and a twelve month high of $78.24.

Establishment Labs (NASDAQ:ESTA) last released its earnings results on Wednesday, November 5th. The company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.16. Establishment Labs had a negative net margin of 43.45% and a negative return on equity of 235.45%. The company had revenue of $53.78 million for the quarter, compared to analysts’ expectations of $52.28 million. During the same quarter last year, the business earned ($0.59) EPS. The firm’s revenue was up 33.8% compared to the same quarter last year. On average, equities research analysts forecast that Establishment Labs will post -2.41 EPS for the current year.

Hedge Funds Weigh In On Establishment Labs

Hedge funds and other institutional investors have recently modified their holdings of the stock. Nantahala Capital Management LLC increased its holdings in Establishment Labs by 11.1% in the 3rd quarter. Nantahala Capital Management LLC now owns 1,973,492 shares of the company’s stock valued at $80,893,000 after acquiring an additional 197,962 shares during the last quarter. Bamco Inc. NY grew its position in shares of Establishment Labs by 30.2% during the third quarter. Bamco Inc. NY now owns 1,181,824 shares of the company’s stock valued at $48,443,000 after purchasing an additional 274,287 shares in the last quarter. Tyro Capital Management LLC increased its holdings in shares of Establishment Labs by 1.0% in the third quarter. Tyro Capital Management LLC now owns 1,077,456 shares of the company’s stock worth $44,165,000 after purchasing an additional 10,735 shares during the last quarter. William Blair Investment Management LLC lifted its position in shares of Establishment Labs by 17.6% in the third quarter. William Blair Investment Management LLC now owns 1,017,543 shares of the company’s stock worth $41,709,000 after buying an additional 152,299 shares in the last quarter. Finally, Mudita Advisors LLP lifted its position in shares of Establishment Labs by 14.3% in the third quarter. Mudita Advisors LLP now owns 686,764 shares of the company’s stock worth $28,150,000 after buying an additional 86,100 shares in the last quarter. Institutional investors own 72.91% of the company’s stock.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.